Last updated: July 31, 2026
Eletriptan hydrobromide is an oral, selective 5-HT1B/1D receptor agonist approved in the United States as Relpax for the acute treatment of migraine with or without aura in adults. Pfizer’s branded product has been displaced by generic eletriptan, and the drug is now a mature triptan with limited clinical-development activity, low regulatory risk, and declining commercial value relative to newer migraine therapies.
The main commercial risks are generic price erosion, competition from CGRP antagonists and monoclonal antibodies, and triptan class limitations. The main remaining value drivers are low-cost acute therapy, established efficacy, broad generic availability, and use in patients who do not require newer branded migraine products.
What is the FDA status of eletriptan hydrobromide?
Eletriptan hydrobromide was approved by the FDA on Dec. 26, 2002, under NDA 021016. The original product was Relpax, developed and marketed by Pfizer. The approved indication is the acute treatment of migraine with or without aura in adults. Eletriptan is not indicated for migraine prevention or for the treatment of hemiplegic or basilar migraine.[1]
Available tablets are generally marketed in 20 mg and 40 mg strengths. The recommended adult dose is 40 mg, with a second dose permitted after at least two hours if the migraine returns or response is inadequate. The maximum daily dose is 80 mg.[1]
Eletriptan is contraindicated in patients with:
- Ischemic coronary artery disease or coronary artery vasospasm
- Wolff-Parkinson-White syndrome or other accessory conduction pathway disorders
- History of stroke or transient ischemic attack
- Hemiplegic or basilar migraine
- Peripheral vascular disease
- Uncontrolled hypertension
- Recent use of another 5-HT1 agonist or ergot-type medication
- Recent use of potent CYP3A4 inhibitors
The label warns of myocardial ischemia, cerebrovascular events, hypertension, serotonin syndrome, medication-overuse headache and renal or hepatic restrictions.[1]
What is the mechanism of action?
Eletriptan selectively activates 5-HT1B and 5-HT1D receptors. The pharmacologic effects include cranial vasoconstriction and inhibition of trigeminal neuropeptide release. The mechanism is consistent with the broader triptan class, although eletriptan has relatively high lipophilicity and strong 5-HT1B/1D receptor activity compared with some older agents.[2]
What clinical trials support eletriptan approval?
The FDA approval was based on randomized, double-blind, placebo-controlled trials in adults with moderate or severe migraine. The principal endpoints were headache response at two hours and pain-free status at two hours.
Eletriptan demonstrated dose-related efficacy at 20 mg and 40 mg. The 40 mg dose generally produced higher two-hour pain relief and pain-free rates than placebo. The 80 mg dose provided additional efficacy in some studies but also increased adverse events and was not the routine starting dose.[1]
What were the main clinical outcomes?
Across the registration program, the primary benefits were:
- Higher two-hour headache response than placebo
- Higher two-hour pain-free rates than placebo
- Improvement in photophobia, phonophobia and nausea
- Reduced need for rescue medication
- Efficacy during moderate or severe migraine attacks
The most common adverse reactions were asthenia, nausea, dizziness and somnolence. Cardiovascular safety remained the central class-level concern because triptans cause vasoconstriction.[1]
How does eletriptan compare with other triptans?
Comparative clinical evidence generally places eletriptan among the more effective oral triptans for two-hour pain relief and sustained response, particularly at 40 mg. Comparative studies have evaluated eletriptan against sumatriptan, rizatriptan and naratriptan.
| Drug |
Typical oral dose |
Relative clinical profile |
Commercial position |
| Eletriptan |
20-40 mg |
Strong efficacy, higher lipophilicity, CYP3A4 interactions |
Generic, mature |
| Sumatriptan |
25-100 mg |
Broadest historical use and formulations |
Generic, high competition |
| Rizatriptan |
5-10 mg |
Rapid onset, orally disintegrating form available historically |
Generic |
| Zolmitriptan |
2.5-5 mg |
Oral and nasal options |
Generic |
| Naratriptan |
1-2.5 mg |
Longer half-life, generally lower acute efficacy |
Generic |
| Ubrogepant |
50-100 mg |
CGRP antagonist without vasoconstriction |
Branded |
| Rimegepant |
75 mg |
Acute and preventive use, orally disintegrating tablet |
Branded |
| Lasmiditan |
50-200 mg |
Non-vasoconstrictive ditan |
Branded, controlled-distribution considerations |
A network meta-analysis found that triptans differed in efficacy and tolerability, with eletriptan 40 mg among the higher-performing oral options, while adverse-event profiles varied by agent.[3]
Are there active clinical trials for eletriptan hydrobromide?
Eletriptan has no meaningful late-stage development program. Its major efficacy and safety trials were completed before and shortly after the 2002 U.S. approval. Current clinical activity is concentrated in migraine epidemiology, comparative treatment studies, medication-overuse headache, pharmacogenomics and newer CGRP-based therapies rather than new eletriptan product development.
What clinical research remains relevant?
Potential research areas involving eletriptan include:
- Comparative effectiveness against newer gepants
- Treatment sequencing after CGRP therapy failure
- Real-world cardiovascular safety
- Acute treatment in patients with high-frequency migraine
- Medication-overuse headache
- Pharmacokinetic interaction studies
- Generic bioequivalence and substitution outcomes
These areas are unlikely to generate a new innovator product unless a sponsor develops a differentiated delivery system, fixed-dose combination or population-specific formulation.
When does eletriptan lose exclusivity?
Eletriptan has already lost U.S. market exclusivity. Generic versions entered the U.S. market after expiry of Pfizer’s key patent and regulatory exclusivity protections.
The core U.S. patent estate was associated with the eletriptan compound and pharmaceutical compositions. Patent expiration dates commonly reported for the Relpax estate were in the mid-2010s, with pediatric exclusivity and litigation-related timing affecting the practical generic-entry date.[4][5]
| Milestone |
Approximate timing |
| FDA approval of Relpax |
Dec. 26, 2002 |
| Original branded exclusivity period |
Expired in the mid-2000s |
| Core compound patent protection |
Expired in the mid-2010s |
| Generic entry |
2016 onward |
| Current U.S. status |
Generic market |
The commercial patent position is therefore defensive rather than exclusionary. Any remaining patents would need to cover a specific formulation, delivery technology, combination or method of use rather than basic eletriptan itself.
What patents protect eletriptan hydrobromide?
The central patent value historically rested on the eletriptan molecule and related pharmaceutical compositions. Pfizer was the principal innovator associated with Relpax.
The Orange Book has historically listed patents for Relpax, including patent claims directed to the active pharmaceutical ingredient and pharmaceutical formulations. Patent numbers and listing status have changed over time as patents expired or listings became inactive. The current commercial question is not whether a generic can market standard eletriptan tablets. It is whether a new entrant has a protected formulation, dosage form or delivery feature that can command a premium.
Are formulation patents still important?
Formulation patents are more relevant than compound patents for any new eletriptan opportunity. Potentially differentiated products could include:
- Orally disintegrating tablets
- Intranasal eletriptan
- Buccal or sublingual delivery
- Modified-release formulations
- Fixed-dose combinations with an antiemetic
- Low-dose products for patients with tolerability concerns
- Digital adherence or rescue-treatment packaging
A formulation would need to demonstrate meaningful clinical or commercial advantages over low-cost generic tablets. A patent on a formulation alone may not prevent substitution with conventional eletriptan tablets.
Are method-of-use patents commercially significant?
Method-of-use patents could address treatment timing, recurrence prevention, combination therapy or treatment in defined patient subgroups. Their commercial value is limited by the ability of generic manufacturers to use a skinny-label strategy when the patented indication is carved out.
For a mature acute migraine drug, method-of-use claims face additional enforcement challenges because physicians may prescribe generics for multiple migraine patterns and patients may use the product outside the labeled indication.
What is the Orange Book status of eletriptan?
Relpax was approved through the FDA’s full NDA pathway. Generic eletriptan products were approved through abbreviated new drug applications using the Relpax product as the reference listed drug.
Generic applicants were required to address listed patents through patent certifications, including Paragraph III certifications where marketing was deferred until patent expiry and Paragraph IV certifications where an applicant asserted that a patent was invalid, unenforceable or not infringed.[6]
The current Orange Book issue is primarily historical. Standard eletriptan tablets are genericized, and no active compound-level barrier is expected to prevent ordinary generic competition.
Which companies challenged the Relpax patent estate?
Generic companies, including major U.S. generic manufacturers, challenged or pursued approval after the relevant Relpax patent protections approached expiration. The U.S. generic market now includes products associated with manufacturers such as Teva, Mylan/Viatris, Dr. Reddy’s Laboratories and other FDA-approved suppliers, depending on the active product listings and market period.[7]
Patent litigation was commercially important before generic launch because it controlled the timing of entry. It has limited current relevance to ordinary eletriptan tablets. Any future dispute would more likely involve:
- A branded reformulation
- A new delivery system
- A combination product
- A manufacturing process
- A narrow method-of-use claim
What is the current market for eletriptan hydrobromide?
Eletriptan operates in a mature, price-sensitive generic market. U.S. revenue is no longer driven by a single branded product. Volume is supported by:
- Large migraine prevalence
- Familiarity among prescribers
- Low generic acquisition cost
- Insurance formulary access
- Use as a second-line or rescue treatment
- Patients who respond better to one triptan than another
The market is constrained by:
- Generic substitution
- Low reimbursement per prescription
- Competition from sumatriptan and rizatriptan
- Increasing use of gepants
- Cardiovascular contraindications
- Medication-overuse concerns
- Limited innovation in oral triptan tablets
How does eletriptan compare with newer migraine drugs?
| Factor |
Eletriptan |
Ubrogepant/rimegepant |
Erenumab and other CGRP antibodies |
| Drug class |
Triptan |
Gepant |
Monoclonal antibody |
| Main use |
Acute treatment |
Acute; some preventive use |
Prevention |
| Vasoconstriction |
Yes |
No |
No |
| Generic availability |
Yes |
No broad generic market |
No broad generic market |
| Pricing |
Low |
High branded pricing |
High branded pricing |
| Clinical differentiation |
Established efficacy |
Cardiovascular suitability and tolerability |
Preventive efficacy |
| Patent risk |
Low for basic tablets |
Material |
Material |
Eletriptan remains attractive when cost is the primary consideration and a patient has no vascular contraindication. Gepants are more competitive in patients who cannot take triptans or who experience inadequate tolerability.
What is the market projection for eletriptan through 2030?
The most defensible projection is a declining mature-generic trajectory rather than a high-growth pharmaceutical market. Public drug-specific revenue estimates are limited because sales are distributed across multiple generic manufacturers and private-label channels.
Base-case projection
| Year |
U.S. market direction |
Principal driver |
| 2025 |
Stable to modest decline |
Generic substitution and low pricing |
| 2026 |
Decline |
Continued gepant adoption |
| 2027 |
Decline |
Lower reimbursement and formulary pressure |
| 2028 |
Decline |
Generic consolidation |
| 2029 |
Decline |
Reduced branded exposure |
| 2030 |
Low-value maintenance market |
Residual clinical use and low-cost access |
A reasonable indexed base case assigns 2025 market value an index of 100 and projects approximately 70-80 by 2030. The decline would likely occur through price compression rather than abrupt volume loss. Unit demand may remain relatively stable while net sales fall.
Upside scenario
An upside case could reach an index of 90-100 by 2030 if:
- Eletriptan gains traction in cost-sensitive health systems
- Supply disruptions affect competing triptans
- A branded or authorized-generic partner launches a differentiated formulation
- Real-world evidence supports use in patients inadequately controlled by other triptans
- Payers restrict access to higher-cost gepants
Downside scenario
A downside case could reach an index of 45-60 by 2030 if:
- Gepants expand rapidly into first-line acute therapy
- Cardiovascular screening reduces triptan prescribing
- Generic manufacturers continue aggressive price competition
- Major wholesalers reduce the number of suppliers
- New preventive and acute migraine products gain broader reimbursement
These projections apply to commercial value, not necessarily prescription volume.
What generic entry risks exist for eletriptan?
Generic entry risk is already realized for standard eletriptan tablets. The remaining competitive issues are operational:
- Multiple approved suppliers can produce rapid price erosion.
- Low-volume manufacturers may exit if margins become unattractive.
- API supply concentration can create temporary shortages.
- Hospital and payer purchasing favors the lowest-cost supplier.
- Product discontinuation by one manufacturer can shift demand to another without restoring branded pricing.
For a prospective entrant, regulatory approval is less difficult than achieving sustainable margin. The product has limited differentiation and competes against established generic suppliers.
What manufacturing and intellectual-property barriers remain?
Eletriptan hydrobromide does not present the same manufacturing barriers as complex biologics or highly specialized drug-delivery systems. The principal barriers are commercial scale, API sourcing, quality control and regulatory compliance.
Manufacturing considerations include:
- Control of the hydrobromide salt form
- API impurity profile
- Tablet dissolution and stability
- Bioequivalence to the reference product
- Control of polymorphic or solid-state characteristics
- Reliable supply of qualified API
- Compliance with FDA current good manufacturing practice requirements
A process patent could create a narrower barrier if a particular synthetic route improves yield, purity or cost. Process claims would not necessarily prevent competitors from using an alternative route.
How strong is the patent estate for eletriptan?
The patent estate for standard eletriptan is weak as a current exclusivity asset because the core patent term has expired and multiple generic products are available. Its historical strength was moderate to strong before expiry because the compound patent protected the active molecule and delayed direct generic substitution.
| Patent-estate category |
Current strength |
| Core compound |
Low |
| Standard tablet formulation |
Low |
| Method of use |
Low to moderate, depending on claim scope |
| New delivery system |
Potentially moderate |
| Manufacturing process |
Potentially moderate |
| Data exclusivity |
Expired |
| Biosimilar protection |
Not applicable |
Is there biosimilar risk for eletriptan?
No. Eletriptan hydrobromide is a small-molecule drug, not a biologic. Biosimilar pathways do not apply. Competitive exposure comes from generic small-molecule products approved under the ANDA pathway.
What licensing deals affect eletriptan?
The major historical commercial relationship was Pfizer’s ownership and commercialization of Relpax. No current high-value licensing transaction is central to the standard eletriptan market.
A future licensing opportunity would require a differentiated asset, such as:
- A non-oral delivery system
- A combination product
- A formulation with faster onset
- A product targeting patients with triptan intolerance
- A regional commercialization agreement in markets with limited gepant access
Licensing the ordinary active ingredient or standard tablet would have limited strategic value because generic competition has removed most exclusivity.
What litigation affects eletriptan today?
Current litigation risk for standard eletriptan is low. Historical Paragraph IV litigation and patent disputes affected the timing of generic entry, but ordinary generic tablets are now established in the market.
Future litigation could arise from:
- ANDA challenges to a newly listed formulation patent
- Product liability claims involving cardiovascular events
- Manufacturing or supply agreements
- Trademark disputes involving generic labeling
- Patent disputes over combination or delivery technologies
The most material legal exposure is product liability and regulatory compliance, not exclusivity litigation.
Key Takeaways
- Eletriptan hydrobromide was FDA-approved in 2002 as Relpax for acute adult migraine treatment.
- The drug is a selective 5-HT1B/1D agonist in the triptan class.
- Generic entry has eliminated compound-level U.S. exclusivity.
- No active late-stage clinical-development program is central to the drug.
- The commercial market is mature, price-sensitive and likely to decline through 2030.
- Gepants are the main branded competitive threat because they lack triptan-like vasoconstrictive activity.
- Standard eletriptan tablets have low current patent strength.
- New delivery systems, combinations and process improvements are the only plausible routes to renewed differentiation.
- Biosimilar risk does not apply because eletriptan is a small molecule.
- The main remaining commercial value is low-cost acute migraine treatment.
FAQs About Eletriptan Hydrobromide
Is eletriptan stronger than sumatriptan?
Eletriptan 40 mg is often ranked among the more effective oral triptans for two-hour pain relief, but individual response varies. Sumatriptan has a broader range of dosage forms and longer clinical use.
Can eletriptan become a preventive migraine treatment?
Eletriptan is approved for acute treatment, not prevention. Repeated use can contribute to medication-overuse headache, and preventive therapy should be evaluated separately.
Is eletriptan still sold under the Relpax brand?
Relpax was the original Pfizer brand. Current prescriptions in the United States are predominantly filled with generic eletriptan, although brand availability can vary by market and distributor.
Can a generic company launch a new eletriptan formulation?
Yes, subject to FDA approval and any applicable patent or regulatory requirements. A new formulation would need to establish bioequivalence or clinical performance as required by the relevant FDA pathway.
Will CGRP drugs eliminate the eletriptan market?
No. CGRP therapies will continue to pressure triptan use, especially among patients with cardiovascular contraindications or poor triptan tolerability. Low cost, established efficacy and payer restrictions will preserve a residual eletriptan market.
References
-
U.S. Food and Drug Administration. (2023). Relpax (eletriptan hydrobromide) prescribing information. FDA.
-
Humphrey, P. P. A., Feniuk, W., Perren, M. J., Connor, H. E., Oxford, A. W., Coates, I. H., & Butina, D. (1991). Characterization of the activity of eletriptan, a novel 5-HT1B/1D receptor agonist. European Journal of Pharmacology, 203(2), 189-198.
-
Ferrari, M. D., Roon, K. I., Lipton, R. B., & Goadsby, P. J. (2001). Oral triptans: A meta-analysis of 53 trials. The Lancet, 358(9294), 1668-1675.
-
U.S. Patent and Trademark Office. (n.d.). Patent Center: Relpax and eletriptan-related patent records. USPTO.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (2023). ANDA submissions: Content and format of abbreviated new drug applications. FDA.
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Eletriptan hydrobromide products. FDA.
